Opamtistomig

奥帕替苏米单抗

Report date: 2026/03/24 20:00:35

Base Information

Drug NameOpamtistomig
Drug Alias NamePD-L1/4-1BB bispecific antibody维利信®LBL-024LBL024
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody
Mechanisms of ActionAnti-Programmed death-ligand 1Tumor necrosis factor receptor superfamily member 9 inhibitors
TargetsProgrammed death-ligand 1Tumor necrosis factor receptor superfamily member 9
Therapy Area/IndicationsSolid tumoursOvarian NeoplasmsTriple Negative Breast Neoplasms +[6] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesNanjing Leadsbiolabs Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesNanjing Leadsbiolabs Co Ltd
Inactive CompaniesN/A
Active IndicationsSolid tumoursOvarian NeoplasmsTriple Negative Breast Neoplasms +[5] 
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A